---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Mechanism of action"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Mechanism of action. Topics: Pharmacologic class: APOL1 function inhibitor; Oral small-molecule inhibitor of APOL1 channel function; Direct binding to APOL1 and inhibition of APOL1-mediated ion flux in cell models; Potency against APOL1 G0, G1, and G2 in channel, trypanolysis, and cell death assays; 5 further topics. 9 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Pharmacologic class: APOL1 function inhibitor

> “apolipoprotein L1 (APOL1) function inhibitor”

Source: [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

> “Vertex has discovered and advanced multiple oral, small molecule inhibitors of APOL1 function, including inaxaplin, pioneering a new class of medicines that targets the underlying cause of this genetic kidney disease.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-2.1.2.6.1-2"></a>

### Oral small-molecule inhibitor of APOL1 channel function

> “The underlying genetic cause of AMKD is a toxic gain-of-function in the APOL1 gene (G1 or G2) thought to enhance APOL1 channel function and damage glomerular cells (e.g., podocytes and endothelial cells) in response to an inflammatory trigger; the resulting cellular damage disrupts the glomerular filtration barrier, resulting in proteinuria, and often leads to accelerated loss of kidney function”
> “Based on the mechanism of disease, targeted inhibition of APOL1 should inhibit glomerular damage, reduce proteinuria, and ultimately slow the progression of kidney disease.”
> “Inaxaplin (previously known as VX-147) is an oral, small molecule inhibitor of APOL1 channel function that has been shown to reduce proteinuria in patients with AMKD in a phase 2a proof-of-concept study”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.6.1-3"></a>

### Direct binding to APOL1 and inhibition of APOL1-mediated ion flux in cell models

> “Our in vitro and in vivo studies showed that inaxaplin bound directly to the APOL1 protein, inhibited APOL1 channel function, and reduced proteinuria in a transgenic mouse model of APOL1-mediated kidney disease.”
> “In this cell model, thallium flux was minimal in the absence of APOL1 expression, and APOL1-mediated thallium flux was nearly eliminated by the administration of inaxaplin (Figure 1B).”
> “Inaxaplin bound directly to APOL1 protein, as shown by a microscale thermophoresis binding assay (Figure 1C).”
> “We hypothesized that the ion-channel function of APOL1 responsible for trypanosome lysis is also the function that is relevant to kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.1.2.6.1-4"></a>

### Potency against APOL1 G0, G1, and G2 in channel, trypanolysis, and cell death assays

> “we determined VX-147 potently inhibited the APOL1 ion channel with IC50 values of 2.3 nM for G0, 1.3 nM for APOL1 G1, and 1.1 nM for APOL1 G2 (Fig. 3A).”
> “We found that VX-147 prevented APOL1-mediated T.b.b. death with essentially equivalent potencies to ion channel inhibition, with EC50 values of 2.0 nM for APOL1 G0, 2.1 nM for APOL1 G1, and 1.2 nM for APOL1 G2 (Fig. 3B).”
> “We saw complete inhibition of APOL1-dependent cell death using VX-147 with EC50 values of 4.3 nM for APOL1 G0, 2.0 nM for APOL1 G1, and 2.2 nM for APOL1 G2 (Fig. 3C).”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

<a id="topic-2.1.2.6.1-5"></a>

### Selectivity: off-target profiling

> “VX-147 was previously shown to bind directly to purified, recombinant APOL1 and broad profiling across a large panel of potential off-targets did not identify any significant activity, indicating that the mechanism of action is due to direct inhibition of the APOL1 ion channel”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

<a id="topic-2.1.2.6.1-6"></a>

### Rationale for limited on-target risk of APOL1 inhibition

> “We reasoned an APOL1 ion channel inhibitor would be likely to have limited on-target safety risk, because there is a published report of an individual with no detectable APOL1 protein expression due to homozygous truncation mutations.”
> “This individual was healthy except for a sensitivity to trypanosome infection”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

<a id="topic-2.1.2.6.1-7"></a>

### Potassium efflux as the proximal driver of APOL1-mediated cell death

> “We demonstrate that efflux of K+, and not influx of Na+, is responsible for APOL1-mediated cell death in our recombinant cell system.”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

<a id="topic-2.1.2.6.1-8"></a>

### Reversal of sodium import, potassium efflux, and downstream injury: independent study

> “In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of GPCR/IP3–mediated calcium release from the ER, impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147.”
> “Our study provides the first detailed biochemical mechanism, to our knowledge, that explains how VX-147 protects kidney cells.”
> “Based on these results, we conclude that the cytoprotective effects of VX-147 are not due to a decrease in G1 protein expression or translocation to the PM.”

Source: [Datta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10904047/)

<a id="topic-2.1.2.6.1-9"></a>

### Blockade of APOL1-dependent calcium influx: independent study

> “Furthermore, we observed that both the M1 (N264K) variant and APOL1 inhibitor, Inaxaplin, exerted protective effects on cell viability by blocking the APOL1-dependent intracellular Ca2+ influx.”

Source: [Adebayo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13743002/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
